HPV Testing: Enhanced Screening for Cervical Cancer in Women 30 Years of Age and Older - Canadian Nurses Association
Cervical cancer is one of the most common types of human papillomavirus (HPV) associated cancers diagnosed in Canada. There has been a significant decrease in the number of women diagnosed with cervical cancer (26% decline over the last 30 years) due to widespread cervical cancer screening and HPV detection. The numbers to-date confirm the positive effect of cytology testing in screening for cervical cancer but also the need for continued screening. The fundamental goal of cervical cancer screening and HPV-associated cytology testing is to prevent morbidity and mortality from cervical cancer. Understanding the link between HPV and cancer has changed how this type of cancer is detected. In fact, deaths from cervical cancer in Canada and the U.S. have declined by about 2% a year due to the widespread use of cytology testing. This program examines the role of HPV testing in cervical cancer and particularly in women 30 years of age and over.
This Self-Learning program has been accredited by the Canadian Nurses Association for up to 1 credit hours. This program has been reviewed and developed by Canadian Nurses Association.
MScN, DNP(c), NP-F|
Aline G. Godcher, RN, MSCN, CCPE, OIIQ license 201-1307
Mona Kamel, MD, BCh, FRCPC
Jeff Habert, MD, CCFP, FCFP
After completion of the program, participants will be able to:
- Identify the risk factors and high-risk populations for cervical cancer.
- Identify available screening tests, including cytology testing (Pap smear test), liquid-based cytology testing (LBC), and co-testing (Pap/HPV).
- Identify the importance of screening and HPV testing for cervical cancer in women 30 years of age and older at high-risk for the HPV (Human Papillomavirus) virus.
- Acknowledge current guidelines regarding HPV testing for cervical cancer in women 30 years of age and older.
- Recommend HPV tests to triage women 30 years of age and older for cervical cancer.